IL6 and type 2 diabetes mellitus: When oxidative stress, inflammation and platelet activation markers were investigated (Table 3), in comparison with HC, T2DM subjects showed significant higher circulating levels of—(i) the in vivo oxidative stress marker 8-iso-PGF2α (p = 0.016), (ii) the in vivo platelet activation marker sCD40L (p < 0.0001), (iii) the subclinical inflammatory marker interleukin-6 (IL-6) (p = 0.0001).